Phase 3 REPLENISH data show secukinumab 150 mg doubled week 52 sustained remission rates vs placebo following a 24-week prednisone taper in adults with relapsing polymyalgia rheumatica.
HealthDay News — Lowering doses of medication to treat opioid use disorder (OUD) during pregnancy is not an effective strategy for preventing severe neonatal opioid withdrawal syndrome (NOWS), ...
Breckenridge Pharmaceutical Inc has recalled 1 lot (PK25110035) of 60mg propranolol hydrochloride extended-release capsules distributed nationwide from October 26 to November 4, 2026, due to potential ...
During the 2026 ACAAI Annual Scientific Meeting, Scott Commins, MD, PhD, describes the clinical nuances and presentation of ...
Supported by phase 3 PREVAIL data, the dual-binding nanobody complement C5 inhibitor provides rapid, sustained functional ...
A survey presented at ACAAI 2026 shows 77% of US allergists attempt to wean patients off asthma biologics after sustained ...
Investigators analyze electronic medical record data to identify real-world patterns and reasons for switching among 6 ...
Research presented at ACAAI 2026 evaluates stock versus personal epinephrine supply requirements, epinephrine availability, ...
An ACAAI 2026 retrospective study shows allergists and immunologists most often diagnose chronic spontaneous urticaria.
Oral remibrutinib demonstrated early and sustained efficacy through 52 weeks across 3 CIndU subtypes in the phase 3 RemIND ...
Biennial screening recommended from ages 50 to 69 years for average-risk men, and annual screening recommended for Black men, non-Blacks with strong family history ...
Approval is supported by phase 3 MAJESTY trial results, which demonstrated that Gazyva was superior to tacrolimus in achieving complete remission of proteinuria at 2 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results